Orexo Sells US Rights to Zubsolv to Dexcel to Repay Debt and Fund AmorphOX Pipeline

An update from Orexo AB ( (SE:ORX) ) is now available.

Orexo AB has agreed to sell the full US rights to its opioid use disorder treatment Zubsolv to Dexcel Pharma USA for a fixed purchase price of USD 91 million plus USD 4–5 million for inventory at closing, and potential contingent payments of up to USD 16.8 million tied to 2026–2027 sales. The deal, expected to close by January 31, 2026, follows a strategic review and will allow Orexo to redeem its outstanding corporate bond and become debt-free, while many US employees will transition to Dexcel to ensure continuity of Zubsolv supply and support. Freed-up capital will be directed toward advancing Orexo’s key growth drivers, including its AmorphOX-based pipeline with rescue medications Izipry for opioid overdose, OX640 for anaphylaxis, and OX390 for adulterated overdoses, the latter co-funded by up to USD 51 million from BARDA, and to expanding AmorphOX into biomolecules such as GLP-1 agonists and vaccines under a partnering-focused business model.

The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.

More about Orexo AB

Orexo AB is a Sweden-based specialty pharmaceutical company focused on treatments for opioid use disorder and other conditions requiring rescue medications. Its portfolio and pipeline center on proprietary drug delivery technology, AmorphOX, with products and candidates targeting opioid overdose, anaphylaxis, and other high-need areas, primarily in the US market.

YTD Price Performance: 34.57%

Average Trading Volume: 90,810

Technical Sentiment Signal: Hold

Current Market Cap: SEK807.6M

For an in-depth examination of ORX stock, go to TipRanks’ Overview page.